Switzerland Pharmaceuticals and Healthcare Report Q1 2015

Switzerland Pharmaceuticals and Healthcare Report Q1 2015

Includes 3 FREE quarterly updates

BMI View :

The Swiss government will need to develop policies to maintain the country's long-term attractiveness as a site for clinical trials, especially as we expect cost of conducting clinical research to rise. The drivers of increased attractiveness of non-traditional locations for clinical studies include improving healthcare infrastructure, more and better trained medical professionals, and a growing requirement for local studies in the pharmaceutical approval process. We foresee a continuing shift in weighting towards emerging markets, especially for Phase III trials, while early-stage research is likely to remain in developed states.

Headline Expenditure Projections

- Pharmaceuticals: CHF7.06bn (USD7.68bn) in 2013 to CHF7.02bn (USD7.34bn) in 2014; -0.66% in local currency terms and -4.4% in US dollar terms.
- Healthcare: CHF68.19bn (USD74.12bn) in 2013 to CHF69.46bn (USD72.63bn) in 2014; +1.9% growth in local currency terms and -2.0% in US dollar terms.
BMI Industry View 7
SWOT 9
Political 11
Economic 12
Industry Forecast 13
Pharmaceutical Market Forecast 13
Table: Pharmaceutical Sales, Historical Data And Forecasts (Switzerland 2010-2018) 14
Healthcare Market Forecast 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Switzerland 2010-2018) 18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Switzerland 2010-2018) 18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Switzerland 2010-2018) 18
Prescription Drug Market Forecast 19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Switzerland 2010-2018) 20
Patented Drug Market Forecast 21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Switzerland 2010-2018) 22
Generic Drug Market Forecast 23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Switzerland 2010-2018) 26
OTC Medicines Market Forecast 27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Switzerland 2010-2018) 28
Pharmaceutical Trade Forecast 29
Table: Pharmaceutical Trade Data And Forecasts (Switzerland 2012-2018) 30
Table: Pharmaceutical Trade Data And Forecasts local currency (Switzerland 2012-2018) 30
Other Healthcare Data 31
Key Risks To BMI's Forecast Scenario 33
Macroeconomic Forecasts 34
Economic Analysis 34
Table: Switzerland - Economic Activity 40
Industry Risk Reward Ratings 41
Western Europe Risk/Reward Index 41
Switzerland Risk/Reward Index 46
Rewards 46
Risks 46
Market Overview 48
Industry Trends And Developments 49
Epidemiology 49
Healthcare Insurance 50
Table: 2013 Health Insurance Premiums 51
Pharmaceutical Wholesale And Retail Sector 53
Research And Development 54
Biotechnology Sector 55
Clinical Trials 57
Regulatory Development 59
Intellectual Property Issues 60
Pricing Regime 60
Reimbursement Regime 65
Competitive Landscape 66
Pharmaceutical Sector 66
Company Profile 71
Novartis 71
Roche 77
Merck Serono 83
GlaxoSmithKline 86
Pfizer 89
Sanofi 91
Merck & Co 93
Demographic Forecast 95
Table: Population Headline Indicators (Switzerland 1990-2025) 97
Table: Key Population Ratios (Switzerland 1990-2025) 97
Table: Urban/Rural Population And Life Expectancy (Switzerland 1990-2025) 98
Table: Population By Age Group (Switzerland 1990-2025) 98
Table: Population By Age Group % (Switzerland 1990-2025) 99
Glossary 100
Methodology 102
Pharmaceutical Expenditure Forecast Model 102
Healthcare Expenditure Forecast Model 102
Notes On Methodology 103
Risk/Reward Index Methodology 104
Index Overview 105
Table: Pharmaceutical Risk/Reward Index Indicators 105
Indicator Weightings 106
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.

Looking for something else?